CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the number of patients with Waldenstrom's
macroglobulinemia that will benefit from treatment with CC-5103 (lenalidomide) and rituximab,
what the side effects are and how long the benefit will last.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Celgene Corporation Genentech, Inc.